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Volume 49, Number 6 Abstracts 1627patients with COPD corrected for other risk factors. The underlying mech-
anism for this remains unknown.
The goal of this study was to assess vascular reactivity as mediated
through both brachial artery flow-mediated (endothelium dependent) and
nitrogen-mediated (endothelium independent) dilatation of the brachial
artery in patients with COPD and controls, and to investigate a potential
relationship between vascular function and airflow obstruction and systemic
inflammation. There were 60 patients with stable COPD studies, of these,
20 were smokers with normal lung function matched for age, sex, and body
weight, and 20 were similarly matched nonsmokers. Patients with known
cardiovascular morbidities were excluded. Systemic inflammatory markers,
including interleukin-6, C-reactive protein, and fibrinogen, were measured.
In patients with stable COPD, flow-mediated and nitrogen-mediated
dilatation of the brachial artery was impaired compared with smoking and
nonsmoking controls. Levels of inflammatory markers such as fibrinogen
and interleukin-6 were higher in COPD patients than in controls. Stepwise
multiple regression analysis showed that baseline brachial diameter, C-
reactive protein level, leukocyte count, blood glucose level, age, sex, and
percentage of predicted forced expiratory volume in 1 second were indepen-
dent predictors of flow-mediated dilatation. Pack-years of smoking did not
have a relationship with flow-mediated dilatation. Baseline brachial artery
diameter was the only independent predictor of nitrogen-mediated dilata-
tion in patients with COPD.
Comment: This study tells us that impaired flow-mediated dilatation is
strongly related to systemic inflammation in airway obstruction. Systemic
inflammation is also related to atherosclerosis. Cardiovascular morbidity and
endothelial dysfunction as measured by flow-mediated brachial artery dila-
tation is an early sign of atherosclerotic risk. Therefore, the study suggests a
link between COPD and atherosclerosis, with both mediated by way of
systemic markers of inflammation. Diabetes also may be a chronic inflam-
matory disease. The precise elements of chronic inflammation that contrib-
ute to all these processes now associated with atherosclerosis certainly
require further investigation.
Outcome and Quality of Life After Surgical and Endovascular Treat-
ment of Descending Aortic Lesions
Dick F, Hinder D, Immer FF, et al. Ann Thorac Surg 2008;85:1605-13.
Conclusion: Long-term quality of life (QOL) is reduced after thoracic
aortic repair. Thoracic endovascular aneurysm repair (TEVAR) patients do
not score higher in QOL compared with open repair patients.
Summary: Health-related QOL is now regarded as an important
variable in the evaluation of any invasive treatment. A small series of QOL
assessments after open aortic repair (OAR) for thoracic aortic pathologies
have found that QOL is impaired after OAR. Studies focusing on abdominal
aortic aneurysm repair have found the QOL is still impaired after endovas-
cular repair of abdominal aortic aneurysms. Similar data are lacking in
patients treated with TEVAR.
The aim of this single-center series was to assess outcome and postop-
erative long-term QOL in patients treated for a variety of thoracic aortic
pathologies by OAR or TEVAR. The results were compared with standard
populations adjusted for age and sex. The study is essentially a post hoc
analysis of a prospectively maintained database. Between January 2001 and
December 2005, 136 patients with a surgical problem of the descending
thoracic aorta were treated at the authors’ institution. Excluded from further
analyses were 14 patients because of concurrent involvement of the ascend-
ing aorta. Fifty-two patients underwent TEVAR and 70 underwent OAR.
Mean follow-up was 34  18 months. End points were perioperative and
late mortality and long-term QOL. QOL was assessed by the Short Form
36-Item Health Survey (SF-36) and the Hospital Anxiety and Depression
Score questionnaires.
TEVAR patients were older than the OAR patients (69  10 vs 62 
15 years; P  .002). Operative mortality did not differ between patients
treated with OAR (9%) and TEVAR (8%; P  .254), and long-term
mortality was similar. Overall QOL scores were 93 (range, 63-110) for OAR
and 83 (range, 60-112) for TEVAR. The QOL scores adjusted for age and
sex in a healthy population range from 85 to 115.
Comment: The results of this study are a bit surprising. However, the
patients were not randomized and the demographics of the TEVAR vs OAR
groups suggest a selection bias favoring entry into the TEVAR arm for
patients aged 65 years and for those with disease confined to the thorax
and those presenting with an emergency situation. These differences in the
baseline characteristics of the patients led the authors to compare their QOL
results with an age- and sex-adjusted standard population rather than to
compare the OAR patients directly with the TEVAR patients. Another
selection bias may result because patients with higher levels of pre-existing
depression and anxiety may be offered the less invasive procedure. Surpris-
ingly, QOL scores in the OAR patients were within the normal range. Those
of the TEVAR were lower compared with the normalized population. The
findings parallel those of the Dutch Randomised Endovascular Aneurysm
Management (DREAM) trial, which also found poor long-term QOL after
EVAR for abdominal aortic aneurysm (N Engl JMed 2005;352:2398-405).
One thing is becoming increasingly clear: underlying comorbidities inpatients with thoracic aortic disease make it rare to truly hit a “home run” in
patients with thoracic aortic pathology, irrespective of what therapy is used.
Patients with Peripheral Arterial Disease in the CHARISMA Trial
Cacoub PP, Bhatt DL, Steg PG, and the CHARISMA Investigators. Eur
Heart J 2009;30:192-201.
Conclusion: Dual antiplatelet therapy consisting of aspirin and clopi-
dogrel provides some benefit vs aspirin alone in patients with peripheral
arterial disease (PAD) with respect to rates of myocardial infarction and
hospitalization for ischemic events. There is an increase in minor bleeding.
Summary: In the Clopidogrel Versus Aspirin in Patients at Risk of
Ischaemic Events (CAPRIE) trial of 6452 patients, clopidogrel reduced the
risk of stroke, vascular death, or myocardial infarction by 23.8% more than
aspirin did in patients with PAD (Lancet 1996;348:1329-39). It is not
known, however, whether the combination of aspirin and clopidogrel is
more effective in patients with PAD in reducing cardiovascular events than a
single antiplatelet agent. That combination was evaluated in patients at risk
for cardiovascular end points in the Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management, and Avoidance (CHA-
RISMA) trial. CHARISMA enrolled patients with atheroembolic disease or
multiple risk factors for atheroembolic events. Dual antiplatelet therapy vs
aspirin alone produced only a nonsignificant 7.1% relative risk reduction in
myocardial infarction, cardiovascular death, or stroke during a median of 28
months (N Engl J Med 2006;354:1706-17).
This article is a post hoc analysis of the subset of patients with PAD
from CHARISMA. In CHARISMA there were 15,603 patients; of those,
2838 had symptomatic PAD and 258 were known to have asymptomatic
PAD. Symptomatic PAD was defined as the presence of intermittent clau-
dication with an ankle-brachial index (ABI) 0.85 or a history of claudica-
tion with a previous intervention. Asymptomatic PADwas defined as an ABI
0.9 in patients with multiple risk factors for atherosclerosis. In CHA-
RISMA, patients with PAD had rates of cardiovascular death, myocardial
infarction, and stroke (primary end point) that were higher than in those
without PAD (8.2% vs 6.8%, hazard ratio [HR], 1.25; 95% confidence
interval [CI], 1.08-1.44; P  .002). In the PAD patients, the primary end
point occurred at 7.6% in the clopidogrel plus aspirin group and at 8.9% in
the placebo plus aspirin group (HR, 0.85; 95% CI, 0.66-1.08; P .18). The
rate of MI was lower in the dual antiplatelet arm than in the aspirin arm
alone, at 2.3% vs 3.7% (HR, 0.63; 95% CI, 0.42-0.96; P .029). The rate of
hospitalization for ischemic events was also lower in the dual antiplatelet
group, at 16.5% vs 20.1% (HR, 0.81; 95% CI, 0.68-0.95; P  .001). Rates
of severe, fatal, or moderate bleeding did not differ between the groups.
Minor bleeding was increased in the dual antiplatelet group, at 34.4% vs
20.8% (odds ratio, 1.99; 95% CI, 1.69-2.34; P  .001).
Comment: With respect to cardiovascular risk, patients with PAD are
clearly the worst among the bad. Symptomatic and asymptomatic PAD
patients have a worse outcome with respect to the CHARISMA end points
than patients with coronary artery disease or with multiple risk factors for
vascular disease but without the actual development of detectable PAD. This
post hoc analysis shows some benefit of dual antiplatelet therapy in the PAD
patients, but it is certainly not the results dreams are made of. Given
increasing evidence that there are genetic determinants of responses to
antiplatelet therapies, whether that be aspirin or clopidogrel, it would seem
that further investigations should focus on identifying which patients with
PAD are likely to benefit the most from dual antiplatelet therapy and where
such benefit clearly exceeds the increased risk of bleeding.
Progression of Peripheral Arterial Disease Predicts Cardiovascular
Disease Morbidity and Mortality
Criqui, MH, Ninomiya JK, Wingard DL, et al. J Am Coll Cardiol 2008;52:
1736-42.
Conclusion: Progression of peripheral arterial disease (PAD), as de-
fined by a decline in ankle-brachial index (ABI)0.15, is associated with an
increased risk of all-cause mortality and cardiovascular mortality.
Summary: PAD is clearly associated with future cardiovascular disease
events and total mortality from cardiovascular disease. Other studies have
demonstrated that the ABI is a risk factor for cardiovascular mortality and is
independent of traditional cardiovascular disease risk factors. Studies exam-
ining the association of PADwith cardiovascular disease outcomes have used
ABI obtained at baseline and have not addressed the potential additional
significance of changes in ABI over time. The current study examined the
association between PAD as measured by ABI with cardiovascular disease
mortality and morbidity in 508 patients (449 men, 59 women) recruited
from two hospital vascular laboratories. Patients had to have had at least two
visits to the vascular laboratory, and ABI and cardiovascular disease risk
factors were measured at the second visit between 1990 and 1994. ABIs
from each patient’s earlier vascular laboratory examination (visit 1) were
abstracted from medical records. Hospital data and vital statistics were used
to track morbidity and mortality for 6 years after the second visit.
